May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Use of the Dry Eye Disease Impact Questionnaire (DEDIQ) in Allergy Patients
Author Affiliations & Notes
  • C.T. Burk
    CTBurk, Inc., Laguna Beach, CA, United States
  • M. Alexander
    Niagra Falls Clinical Research, Niagara Falls, ON, Canada
  • J. Walt
    Allergan, Inc., Irvine, CA, United States
  • J. Lee
    Global Health Outcomes, Allergan, Inc., Irvine, CA, United States
  • Footnotes
    Commercial Relationships  C.T. Burk, Allergan, Inc C; M. Alexander, Allergan, Inc. R; J. Walt, Allergan, Inc. E; J. Lee, Allergan, Inc. E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3734. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.T. Burk, M. Alexander, J. Walt, J. Lee; Use of the Dry Eye Disease Impact Questionnaire (DEDIQ) in Allergy Patients . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3734.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To assess the reliability of the Dry Eye Disease Impact Questionnaire (DEDIQ©) over time and to compare the DEDIQ© to the Ocular Surface Disease Index(OSDI©), a validated instrument used in dry eye patients. Methods: The DEDIQ© is a questionnaire consisting of 33 items that evaluate patients' dry eye symptoms and their actions taken as a result of these symptoms in various time periods. This questionnaire was administered to allergy patients from a single allergy clinic. Test-retest reliability was assessed by correlating baseline DEDIQ© scores with DEDIQ© scores assessed one month following the baseline questionnaire. Validity was assessed for items on the DEDIQ© and the OSDI© questionnaires. While the DEDIQ© and OSDI© subscales were created a priori, this study focused on item correlation using the Pearson's and Spearman correlation coefficients (r) as appropriate. Results: The DEDIQ was administered to a total of 32 patients, the final test-retest analyses included participants who completed at least 70% of the items (n=18). The highest correlations for test-retest items were frequency and severity of blurred vision, frequency of having tired/fatigued eyes, severity of blinking, and overall severity of symptoms (r≥ 0.70, p<0.05). Analysis of validity for the OSDI© and the DEDIQ© included 10 patients who completed both questionnaires. Highest correlations between the OSDI© and DEDIQ© were found for sensitivity to light and use of Rx anti-allergy/anti-inflammatory drops, as well as certain dry eye symptoms and frequency of visits to health care practitioners, respectively (r≥ 0.70, p<0.05). Exposure to environmental conditions such as air conditioning and low humidity also correlated to the frequency of dry eye symptoms(r≥ 0.70, p<0.05). Conclusions: The DEDIQ© demonstrates acceptable reliability over time and validity was found when compared to a previously validated questionnaire. Advantages of the DEDIQ© over the OSDI© include dry-eye specific questions regarding impact of the disease on patients' function and resource utilization.

Keywords: cornea: tears/tear film/dry eye • clinical (human) or epidemiologic studies: pre • clinical (human) or epidemiologic studies: hea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.